par Santens, Patrick;Ventura, Manfredi
Référence Acta neurologica belgica, 103, 3, page (159-163)
Publication Publié, 2003-09
Article révisé par les pairs
Résumé : In this report the results of a Belgian multicenter 24-week open-label study with donepezil in the treatment of mild to moderate Alzheimer's disease are described. Efficacy and safety were evaluated in a sample of 200 patients recruited in 25 Belgian centers. No significant changes could be found in cognition and behaviour over this 6-month period. Changes in daily functioning were small. Safety data were comparable to those reported in international trials. These results suggest that the findings of more robust double-blind, placebo-controlled studies can be confirmed in real life situations.